Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

dc.contributor.authorSuarez-Almazor, Maria
dc.contributor.authorPundole, Xerxes
dc.contributor.authorAbdel-Wahab, Noha
dc.contributor.authorJohnson, Douglas
dc.contributor.authorGupta, Dipti
dc.contributor.authorGlezerman, Ilya
dc.contributor.authorCooksley, Tim
dc.contributor.authorAnderson, Ronald
dc.contributor.authorBlidner, Ada Gabriela
dc.contributor.authorChoi, Jennifer
dc.contributor.authorDougan, Michael
dc.contributor.authorGinex, Pamela
dc.contributor.authorGirotra, Monica
dc.contributor.authorShannon, Vickie R.
dc.contributor.authorRapoport, Bernardo Leon
dc.contributor.emailbernardo.rapoport@up.ac.zaen_ZA
dc.date.accessioned2020-10-26T11:51:41Z
dc.date.issued2020-12
dc.description.abstractImmune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.en_ZA
dc.description.departmentImmunologyen_ZA
dc.description.embargo2021-08-20
dc.description.librarianhj2020en_ZA
dc.description.sponsorshipThe Cancer Association of South Africa (CANSA), the National Research Foundation (NRF) of South Africa and the NIH/NCI (Cancer Center Support Grant P30 CA008748).en_ZA
dc.description.urihttp://link.springer.com/journal/520en_ZA
dc.identifier.citationSuarez-Almazor, M.E., Pundole, X., Abdel-Wahab, N. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care in Cancer 28, 6159–6173 (2020). https://doi.org/10.1007/s00520-020-05710-8.en_ZA
dc.identifier.issn0941-4355 (print)
dc.identifier.issn1433-7339 (online)
dc.identifier.other10.1007/s00520-020-05710-8
dc.identifier.urihttp://hdl.handle.net/2263/76607
dc.language.isoenen_ZA
dc.publisherSpringeren_ZA
dc.rights© Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520.en_ZA
dc.subjectArthralgiaen_ZA
dc.subjectImmune checkpoint inhibitor (ICI)en_ZA
dc.subjectArthritisen_ZA
dc.subjectCardiomyopathyen_ZA
dc.subjectCorticosteroidsen_ZA
dc.subjectMyocarditisen_ZA
dc.subjectMyositisen_ZA
dc.subjectImmunomodulation agentsen_ZA
dc.subjectOther immunosuppressive agentsen_ZA
dc.subjectPolymyalgiaen_ZA
dc.titleMultinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsen_ZA
dc.typePostprint Articleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
SuarezAlmazor_Multinational_2020.pdf
Size:
442.65 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Immunology)
Research Articles (University of Pretoria)
Simple item page